Information Provided By: 
Fly News Breaks for March 5, 2019
MYOK
Mar 5, 2019 | 09:24 EDT
BMO Capital analyst Kelly Bania raised her price target on MyoKardia to $90 and kept her Outperform rating, saying its latest PIONEER open-label extension results support the mavacamten efficacy and safety in oHCM patients while also posing a "positive read-through to the ongoing Phase 3 EXPLORER trial for oHCM". Bania notes that her new price target reflects a 10% increase in probability of success of mavacamten in oHCM and nHCM to 70% and 50% respectively.
News For MYOK From the Last 2 Days
There are no results for your query MYOK
